Ahmad Mouhannad, Crescenti Fabio
Aller-Weser-Klinik, Verden (Aller), Germany.
Surg J (N Y). 2019 May 10;5(1):e28-e34. doi: 10.1055/s-0039-1687857. eCollection 2019 Jan.
Peritoneal adhesions reoccur in up to 100% of cases, possibly causing complications like pain, secondary female infertility, and small bowel obstruction. The latter has a mortality rate of up to 15% during hospitalization. This study investigates if recurrence of peritoneal adhesions can be prevented by prophylactic use of the starch-based medical device 4DryField. The course of 40 patients with surgery for intestinal obstruction and, partially, second intervention was analyzed. In both operations, adhesion severity and extent were scored 0 (no adhesions) to III (massive/dense and vascular adhesions) and 0 (no adhesions) to III (extensive, covering more than approximately 25 × 25 cm), respectively. To prevent recurrence of adhesions all patients were treated with 4DryField gel (60 mL saline solution per 5 g powder), evenly distributed on the whole impaired intestine (including anastomoses) before abdominal closure. Follow-up was up to 1.5 years in a 3 to 6 months' interval. Eight patients had relaparotomies on postoperative days 1 to 155. In the first operation, median adhesion severity score was III, median adhesion extent II. In redo-surgeries, significantly lower scores were detected (median adhesion severity: 0, = 0.0003; median adhesion extent: 0, = 0.0009). No adverse events related to the product were observed. One patient had later redo-surgery in another hospital due to recurrence of adhesions, one patient suffered from flatulence. All other patients were free of adhesion-related symptoms during follow-up. Based on the high severity of diseases and the significant reduction of adhesion severity and extent in redo-surgeries, 4DryField gel is a promising adjunct for adhesion prevention in bowel surgery. The favorable results should be confirmed in prospective randomized trials.
腹膜粘连在高达100%的病例中会复发,可能导致疼痛、继发性女性不孕和小肠梗阻等并发症。后者在住院期间的死亡率高达15%。本研究调查了预防性使用淀粉基医疗器械4DryField是否可以预防腹膜粘连的复发。 分析了40例肠梗阻手术患者的病程,部分患者进行了二次干预。在两次手术中,粘连严重程度和范围分别评分为0(无粘连)至III(大量/致密和血管粘连)和0(无粘连)至III(广泛,覆盖面积超过约25×25 cm)。为防止粘连复发,所有患者在腹部关闭前均用4DryField凝胶(每5 g粉末加60 mL盐溶液)治疗,均匀分布于整个受损肠段(包括吻合口)。随访间隔为3至6个月,最长达1.5年。 8例患者在术后1至155天进行了再次剖腹手术。在首次手术中,粘连严重程度中位数评分为III,粘连范围中位数评分为II。在再次手术中,检测到的评分显著降低(粘连严重程度中位数:0, = 0.0003;粘连范围中位数:0, = 0.0009)。未观察到与该产品相关的不良事件。1例患者后来因粘连复发在另一家医院进行了再次手术,1例患者出现肠胃胀气。所有其他患者在随访期间均无粘连相关症状。 基于疾病的高严重性以及再次手术中粘连严重程度和范围的显著降低,4DryField凝胶是肠道手术中预防粘连的一种有前景的辅助手段。这些良好结果应在前瞻性随机试验中得到证实。